MIDDLE EAST AND AFRICA PARENTERAL NUTRITION MARKET

Tpn 3bag.jpg

 

Parenteral nutrition (PN) is the feeding of a person intravenously, bypassing the usual process of eating and digestion. The person receives nutritional formulae that contain nutrients such as glucose, salts, amino acids, lipids and added vitamins and dietary minerals. It is called total parenteral nutrition (TPN) or total nutrient admixture (TNA) when no significant nutrition is obtained by other routes, and partial parenteral nutrition (PPN) when nutrition is also partially enteric. It may be called peripheral parenteral nutrition (PPN) when administered through vein access in a limb rather than through a central vein as central venous nutrition (CVN).

  • The MEA parenteral nutrition market is expected to reach USD 377.1 million by 2025 according to a new report by Grand View Research, Inc.
  • The MEA parenteral nutrition market is expected to witness lucrative growth over the forecast period owing to various parameters such as presence of large pool of malnourished children, rising premature births, increasing adoption by healthcare settings for nutrient administration in chronically ill geriatric patients, and rising prevalence rate of cancer within the region.
  • Increasing prevalence of chronic conditions such as cancer unswervingly influences the use of parenteral nutrition across the globe.
  • Parenteral nutrition helps in the administration of key vital nutrients that are useful in maintaining strength, energy, and hydration level in cancer patients, thus, acting a vital impact rendering driver expected to surge market growth over the forecast period.

The MEA parenteral nutrition market is expected to reach USD 377.1 million by 2025 according to a new report by Grand View Research, Inc. The MEA parenteral nutrition market is expected to witness lucrative growth over the forecast period owing to various parameters such as presence of large pool of malnourished children, rising premature births, increasing adoption by healthcare settings for nutrient administration in chronically ill geriatric patients, and rising prevalence rate of cancer within the region.

Increasing prevalence of chronic conditions such as cancer unswervingly influences the use of parenteral nutrition across the globe. Parenteral nutrition helps in the administration of key vital nutrients that are useful in maintaining strength, energy, and hydration level in cancer patients, thus, acting a vital impact rendering driver expected to surge market growth over the forecast period.

Similarly, predominant existence of malnourished children and premature neonates that require these nutrients, is expected to further propel the growth. According to statistics published by the Knoema, a public data platform, the prevalence of the malnutrition in Middle East and North Africa in 2013 was around 6.04%, however, it has witnessed a decline over the period of time.

Further key findings:

  • Single dose amino acid solutions held a dominant share in 2016. This dominance is governed by the influx of innovative products. In addition, these innovative formulations are more efficient and cause lesser adverse effects.
  • Intravenous lipid emulsions are anticipated to witness lucrative growth over the forecast period. Drug delivery through lipid emulsion is expected to showcase promising results as it results in minimal adverse effects such as irritation, pain, and thrombophlebitis.
  • Bags dominated the Middle East parenteral nutrition market with more than 67.00% share in 2016. These packaging materials are easy to handle, transport, and are cost-efficient.
  • Vials are used for smaller concentration dose, often in hospital compounding. Increasing focus on customized treatment is likely to boost the usage of vials.
  • Saudi Arabia held largest share in MEA parenteral nutrition market in 2016. However, countries such as Kuwait, Oman, Lebanon, and Jordan are anticipated to gain remunerative share over the forecast period.
  • Key market players of the MEA parenteral nutrition industry are B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Hospira Inc.; Qatar Pharma Factory; Pharmaceutical Solutions Industry; Kuwait Saudi Pharmaceutical Industries Co.; Alfa Laboratories; and Well Pharma.
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s